Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pseudomonas paraeruginosa PA7

ABSTRACT: A "superbug" resistant to many third generation antibiotics

PROVIDER: PRJNA16720 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR9418200.fastq.gz	Fastqsanger.gz
	SRR9418201.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Pseudomonas paraeruginosa

Project description:Pseudomonas paraeruginosa overview

| PRJNA1062961 | ENA

Klebsiella pneumoniae

Project description:Third generation cephalosporin-resistant Klebsiella pneumoniae isolates

| PRJNA721894 | ENA

Lethal Antibiotic Exposure Drives the Convergent Evolution of High Tolerance Phenotype Conferred by nfxB Mutation in clinically relevant Pseudomonas aeruginosa

Project description:Fluoroquinolone antibiotics, a common antibiotic for the treatment of Pseudomonas aeruginosa infection, are facing challenges due to the rapid evolution of bacterial resistance. Through designed evolutionary experiments in vitro, we find that there are significant differences in evolutionary trajectories and outcomes of resistant bacteria obtained in different induction modes, among which fitness benefit of resistant strains obtained in high-dose induction mode under high level of antibiotic is significantly higher than that of wild-type strain, and collateral sensitivity to aminoglycosides and some other antibiotics will be obtained. Resistance strains obtained in the low-dose induction mode exhibit higher heterogeneity, which is accompanied by multiple drug resistance (MDR). Through second generation resequencing and proteomic techniques, overexpression of MexCD-OprJ efflux pump induced by mutations in the nfxB gene significantly improved the fitness benefit of Pseudomonas aeruginosa PAO1 under high level of fluoroquinolones. This is the precondition of the further evolution of the fleroxacin-resistant strains in the high dose induction mode, the addition of the efflux pump inhibitor phenylalanyl arginyl β-naphthylamide (PAβN) could effectively repress the evolution of bacterial resistance in the high dose induction mode. Fleroxacin use followed by gentamicin helped drive infectious P.aeruginosa to extinction, causing nfxB mutation to cause collateral sensitivity to gentamicin.

2025-02-15 | PXD044054 | Pride

Escherichia coli strain:field strain

Project description:CMY-2 producing third generation cephalosporin resistant E. coli

| PRJDB8169 | ENA

Escherichia coli

Project description:fluoroquinolones and third-generation cephalosporins resistant Escherichia coli strains

| PRJNA628558 | ENA

Project description:WGS analysis of third-generation cephalosporin resistant Escherichia coli

| PRJNA844174 | ENA

Escherichia coli

Project description:Third generation cephalosporin resistant Escherichia coli (CREC) genome sequencing

| PRJNA862705 | ENA

Staphylococcus aureus

Project description:Study on the evolution mechanisms of MRSA third-generation tetracycline antibiotics resistance

| PRJNA940613 | ENA

Pseudomonas paraeruginosa strain:MAZ105

Project description:Pseudomonas paraeruginosa strain:MAZ105 Genome sequencing and assembly

| PRJNA940804 | ENA

An Outer Membrane Protein-Targeting Antibiotic Against Resistant Gram-Negative Bacterial Pathogens

Project description:There is an urgent need for novel antibiotics against carbapenem and 3rd generation cephalosporin-resistant Gram-negative pathogens, for which the last-resort antibiotics have lost most of their efficacy. We describe here a novel class of synthetic antibiotics that was inspired from natural product-derived scaffolds. The antibiotics have an unprecedented mechanism of action, which targets the main component (BamA) of the Bam folding machinery required for folding and insertion of ß-barrel proteins into the outer membrane of Gram-negative bacteria. This OMPTA (outer membrane protein-targeting antibiotic) class shows potent activity against multidrug-resistant Gram-negative ESKAPE pathogens and overcomes colistin-resistance both in vitro and in vivo. A clinical candidate has the potential to address life threatening Gram-negative infections with high unmet medical need.

2020-02-04 | MSV000084899 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data